Home › ArcherDX To Collaborate With Illumina On Next-Generation Sequencing-Based In Vitro Diagnostics Development
 

Keywords :   


ArcherDX To Collaborate With Illumina On Next-Generation Sequencing-Based In Vitro Diagnostics Development

2016-06-01 06:27:33| drugdiscoveryonline Home Page

ArcherDX, Inc. recently announced an agreement to develop next-generation sequencing (NGS)-based in vitro diagnostic (IVD) tests with Illumina, Inc. Under terms of the agreement, ArcherDX will lead the development of a series of diagnostic tests utilizing ArcherDX’s Anchored Multiplex PCR (AMP) chemistry that will be run on the Illumina MiSeqDx instrument

Tags: development vitro diagnostics collaborate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05'Garden floods show need to work with nature'
03.05Worst-ever job interviews: 'We had to crawl and moo'
03.05Have the wheels come off for Tesla?
03.05BW Converting focuses on time, energy and cost savings at INFOFLEX
03.05Navigator Paper Ups Offer for Accrual
03.05Dilo Hosts Open House
03.05Spate Releases Top-Rising Skin Care Ingredients Report with Grant Industries
03.05Fedrigoni Self-Adhesives introduces compostable label material
More »